糖尿病药物市场 - 全球产业规模、份额、趋势、机会及预测（按药物类别、糖尿病类型、给药途径、分销管道、地区和竞争格局划分，2021-2031年）

全球糖尿病治疗市场预计将从 2025 年的 912.3 亿美元成长到 2031 年的 1,399.3 亿美元，年复合成长率为 7.39%。

这些药物，包括胰岛素和口服降血糖药，对于调节第1型和第2型糖尿病患者的血糖值至关重要。推动这一市场成长的主要因素是全球慢性代谢性疾病发生率的上升，而这又与人口老化、都市化和肥胖率上升密切相关。越来越多的患者需要持续的药物治疗来控制病情并预防严重的生理併发症。根据国际糖尿病联盟（IDF）预测，到2024年，全球将有约5.89亿成年人罹患糖尿病。

儘管市场需求强劲，但先进治疗方法的高昂费用是阻碍市场发展的主要障碍，这限制了开发中国家的用药途径。新型生物製药及其长期治疗的高昂成本往往难以在价格敏感族群中广泛应用。因此，低收入地区缺乏可负担性以及报销体係不完善仍然是全球製药业在该领域实现最佳成长的主要障碍。

市场驱动因素

全球糖尿病盛行率的快速成长，尤其是肥胖率上升和久坐不动的生活方式，是推动全球糖尿病治疗市场发展的主要动力。患者群体的快速扩大，使得已开发国家和开发中国家都迫切需要有效的药物疗法。随着代谢性疾病的日益普遍，医疗卫生系统被迫优先考虑可及的治疗方法，以减少长期併发症，从而确保製药公司稳定的收入来源。为了说明这项负担的严重性，非传染性疾病风险因子合作组织和世界卫生组织（世卫组织）在2024年11月估计，到2022年，全球将有8.28亿成年人患有糖尿病。

同时，新型治疗药物和生物製药，特别是Glucagon-Like Peptide-1(GLP-1) 受体促效剂的引入，正在从根本上改变竞争格局。这些先进疗法凭藉其强效血糖控制和显着体重管理的双重优势，推动了市场扩张，并改变了处方趋势，使其不再依赖传统的口服降血糖药物。这种临床疗效正转化为产业主要创新者的显着财务成长。例如，2024年11月，诺和诺德公司报告称，其用于治疗第2型糖尿病的GLP-1类药物在当年前九个月的销售额成长了26%。 2024年10月，礼来公司宣布，其糖尿病治疗药物Munjaro仅在第三季就实现了31.1亿美元的全球收入。

市场挑战

先进治疗方法的高成本对全球糖尿病药物市场构成重大障碍，尤其是在价格敏感且疾病负担成长最快的地区。儘管患者人数不断增加，但引进新型高效药物的经济能力往往落后。在许多开发中国家，有限的健保报销体系迫使病患自费，这种经济差距限制了高端生物製药在富裕国家的市场渗透，导致全球很大一部分人口依赖利润微薄的学名药。

这种经济差距直接阻碍了製药业从不断增长的患者群体中获利的能力。管理这种疾病的巨额资金表明，它给全球医疗保健系统带来了沉重的负担。根据国际糖尿病联盟（IDF）估计，到2024年，全球与糖尿病相关的医疗保健费用将达到1兆美元。然而，由于大部分支出集中在高所得国家，製药公司面临结构性成长限制。新兴市场仍未能充分利用患者群体，因为这些患者群体获得最盈利治疗方法的机会有限。

市场趋势

超长效、每週一次的基础胰岛素的问世，标誌着在减轻每日註射负担方面取得了重大突破，而每日註射往往会降低患者的治疗依从性。这项创新采用了一种新的配方，延长了基础胰岛素的半衰期，简化了第二型糖尿病患者的治疗方案。研发人员正在推动这些候选药物的临床试验，以证明其疗效不劣于标准治疗方案。根据礼来公司2024年9月发布的关于QWINT III期临床试验的新闻稿，每週一次的胰岛素Efitra alfa在52週时使糖化血红蛋白（A1C）水平降低了1.31%，其疗效与每日註射甘精胰岛素相当。

同时，经济实惠的胰岛素生物相似药正日益渗透市场，为生物製药提供价格较亲民的替代方案，从而改变整个产业格局。专利到期以及医疗系统在确保患者用药可及性的同时降低采购成本的需求，推动了这一趋势的发展。这些药物的快速商业性化应用表明，全球支付方对其接受度正在不断提高。根据山德士2024年11月发布的报告，其生物相似药部门今年前九个月的销售额达到21亿美元，以外汇汇率计算增加了32%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球糖尿病药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类别（胰岛素、DPP-4抑制剂、GLP-1受体促效剂、SGLT2抑制剂、其他）
  • 依糖尿病类型（第一型糖尿病、2 型糖尿病、妊娠糖尿病）
  • 给药途径（口服、皮下注射、静脉注射）
  • 按分销管道（网上药局、医院药局、零售药局、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美糖尿病药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲糖尿病药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区糖尿病药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲糖尿病药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲糖尿病药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球糖尿病药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Novo Nordisk A/S
• Sanofi
• Merck & Co., Inc.
• Eli Lilly and Company
• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Novartis AG
• Bayer AG
• Pfizer Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Diabetes Drugs Market is projected to expand from a valuation of USD 91.23 Billion in 2025 to USD 139.93 Billion by 2031, reflecting a CAGR of 7.39%. These pharmaceutical agents, including insulin and oral hypoglycemics, are essential for regulating blood glucose levels in patients diagnosed with Type 1 and Type 2 diabetes. The central catalyst for this market growth is the rising global incidence of chronic metabolic disorders, driven by aging demographics, urbanization, and increasing obesity rates. This expanding patient population necessitates continuous pharmacotherapy to manage the condition and prevent severe physiological complications; according to the International Diabetes Federation, approximately 589 million adults were living with diabetes worldwide in 2024.

Despite this strong demand, a major obstacle potentially hindering market progress is the prohibitive cost of advanced treatment regimens, which limits accessibility in developing economies. The significant financial expense associated with newer biologics and long-term management often restricts widespread adoption among price-sensitive populations. Consequently, the lack of affordability and inadequate reimbursement structures in low-income regions remain substantial barriers to the optimal growth of the global pharmaceutical sector in this domain.

Market Driver

The surging global prevalence of diabetes, significantly intensified by rising obesity rates and sedentary lifestyles, serves as the primary force propelling the Global Diabetes Drugs Market. This rapidly growing patient base creates an urgent and sustained need for effective pharmacotherapy across both developed and developing nations. As metabolic disorders become more pervasive, healthcare systems are compelled to prioritize accessible treatments to mitigate long-term complications, thereby securing a consistent revenue stream for pharmaceutical manufacturers; highlighting the scale of this burden, the NCD Risk Factor Collaboration and the World Health Organization estimated in November 2024 that 828 million adults globally were living with diabetes in 2022.

Concurrently, the adoption of novel therapeutic classes and biologics, particularly Glucagon-Like Peptide-1 (GLP-1) receptor agonists, is fundamentally reshaping the competitive landscape. These advanced therapies are driving market expansion by offering the dual benefits of robust glycemic control and significant weight management, shifting prescription trends away from traditional oral hypoglycemics. This clinical efficacy has translated into substantial financial growth for key industry innovators; for instance, Novo Nordisk reported in November 2024 that sales of GLP-1-based products for type 2 diabetes increased by 26% during the first nine months of the year, while Eli Lilly and Company announced in October 2024 that worldwide revenue for the diabetes medication Mounjaro reached $3.11 billion in the third quarter alone.

Market Challenge

The high cost of advanced therapeutic regimens constitutes a significant barrier to the Global Diabetes Drugs Market, particularly in price-sensitive regions where the disease burden is growing most rapidly. Although the patient population is expanding, the economic capacity to adopt newer, high-efficacy pharmaceutical agents often lags behind. In many developing economies, limited reimbursement frameworks force patients to rely on out-of-pocket payments, a financial disparity that restricts the market penetration of premium biologics to wealthy nations while leaving a vast segment of the global population dependent on older, lower-margin generic alternatives.

This affordability gap directly impedes the industry's ability to monetize the widening patient base. The financial magnitude of managing this condition illustrates the strain on global health systems; according to the International Diabetes Federation, diabetes was responsible for an estimated USD 1 trillion in global health expenditure in 2024. However, because a significant portion of this spending is concentrated in high-income nations, pharmaceutical companies face a structural limit on growth, as they remain unable to fully capitalize on the volume of patients in emerging markets who are financially excluded from accessing the most profitable treatment options.

Market Trends

The introduction of Ultra-Long-Acting Once-Weekly Basal Insulins represents a critical shift aimed at mitigating the burden of daily injections, which often compromises treatment adherence. This innovation utilizes novel formulations to extend basal insulin half-life, simplifying treatment schedules for Type 2 diabetes patients. Developers are advancing these candidates through trials to prove non-inferiority against daily standards; according to Eli Lilly and Company's September 2024 press release regarding the Phase 3 QWINT clinical trials, the once-weekly insulin efsitora alfa demonstrated efficacy by reducing A1C levels by 1.31% at week 52, comparable to daily insulin glargine.

Simultaneously, the increasing market penetration of Cost-Effective Insulin Biosimilars is reshaping the sector by offering affordable alternatives to biologic originators. This trend is accelerated by patent expirations and the need for healthcare systems to lower procurement costs while maintaining patient access. The rapid commercial uptake of these agents highlights their growing acceptance among global payers; according to Sandoz's November 2024 report, global net sales for the company's biosimilars division reached USD 2.1 billion for the first nine months of the year, marking a 32% increase in constant currencies.

Key Market Players

• Novo Nordisk A/S
• Sanofi
• Merck & Co., Inc.
• Eli Lilly and Company
• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Novartis AG
• Bayer AG
• Pfizer Inc.

Report Scope

In this report, the Global Diabetes Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetes Drugs Market, By Drug Class

• Insulin
• DPP-4 Inhibitors
• GLP-1 Receptor Agonists
• SGLT2 Inhibitors
• Others

Diabetes Drugs Market, By Diabetes Type

• Type 1
• Type 2
• Gestational

Diabetes Drugs Market, By Route of Administration

• Oral
• Subcutaneous
• Intravenous

Diabetes Drugs Market, By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
• Others

Diabetes Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetes Drugs Market.

Available Customizations:

Global Diabetes Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diabetes Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others)
  • 5.2.2. By Diabetes Type (Type 1, Type 2, Gestational)
  • 5.2.3. By Route of Administration (Oral, Subcutaneous, Intravenous)
  • 5.2.4. By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Diabetes Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Diabetes Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Diabetes Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Diabetes Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Diabetes Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Diabetes Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Diabetes Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Diabetes Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Diabetes Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Diabetes Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Diabetes Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Diabetes Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Diabetes Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Diabetes Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Diabetes Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Diabetes Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Diabetes Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Diabetes Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Diabetes Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Diabetes Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Diabetes Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Diabetes Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Diabetes Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Diabetes Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Diabetes Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Diabetes Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Diabetes Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Diabetes Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Diabetes Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Diabetes Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Diabetes Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Diabetes Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Diabetes Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Diabetes Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Diabetes Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Diabetes Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Diabetes Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Diabetes Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Diabetes Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Diabetes Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Diabetes Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Diabetes Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Diabetes Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Diabetes Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Diabetes Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Diabetes Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Diabetes Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Diabetes Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Diabetes Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novo Nordisk A/S
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi
• 15.3. Merck & Co., Inc.
• 15.4. Eli Lilly and Company
• 15.5. AstraZeneca PLC
• 15.6. Takeda Pharmaceutical Company Limited
• 15.7. Boehringer Ingelheim International GmbH
• 15.8. Novartis AG
• 15.9. Bayer AG
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer